Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer

• প্রধান লেখক: Masafumi Yasunaga (লেখক), Hideaki Yahata (লেখক), Kaoru Okugawa (লেখক), Mototsugu Shimokawa (লেখক), Yumiko Maeda (লেখক), Emiko Hori (লেখক), Keisuke Kodama (লেখক), Hiroshi Yagi (লেখক), Tatsuhiro Ohgami (লেখক), Ichiro Onoyama (লেখক), Kazuo Asanoma (লেখক), Kiyoko Kato (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Elsevier, 2022-09-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Objective: Recent randomized phase III trial has shown significant benefit in overall survival (OS) for patients with advanced cervical cancer by adding bevacizumab to conventional chemotherapy. The aim of this study was to evaluate the prognostic impact for Japanese recurrent, persistent, or metast...